A SURVEY OF NONXANTHINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biochemistry

Background:

• Adenosine receptors (A₁, A_2a, A₃) are crucial drug targets.
• Understanding ligand binding is key for developing novel therapeutics.
• Heterocyclic compounds represent a rich source of potential drug candidates.

Purpose of the Study:

• To determine binding affinities of diverse heterocyclic derivatives at rat adenosine receptors.
• To identify novel adenosine receptor antagonists and selective ligands.
• To explore structure-activity relationships for adenosine receptor modulation.

Main Methods:

• Radioligand binding assays using [³H]PIA, [³H]CGS 21680, and [¹²⁵I]AB-MECA.
• Screening of mono-, bi-, tricyclic, and macrocyclic compounds.
• Utilizing rat brain membranes and stably transfected CHO cells expressing rat A₃ receptors.

Main Results:

• Identification of new classes of adenosine antagonists, including 5-oxoimidazopyrimidines and pyrazoloquinazolines.
• Selective binding of sulfonylpiperazines, 11-hydroxytetrahydrocarbazolenine, 4H-pyrido[1,2-a]pyrimidinone, folic acid, and cytochalasins H and J to A₃ receptors.
• Cytochalasin A demonstrated A₁ adenosine receptor binding and inhibited adenylyl cyclase in rat adipocytes, independent of reversible receptor binding.

Conclusions:

• The study identified novel heterocyclic compounds with significant binding affinities for adenosine receptors.
• Several compounds exhibit selectivity for the A₃ adenosine receptor, offering potential for targeted drug development.
• Cytochalasin A's activity suggests complex interactions with adenosine receptors and downstream signaling pathways.